Jan 31 |
EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic
|
Jan 31 |
Orgenesis to buy stake in Octomera for advancing immuno-oncology portfolio
|
Jan 31 |
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
|
Jan 19 |
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
|
Nov 14 |
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
|
Nov 13 |
Orgenesis GAAP EPS of $0.43
|
Nov 13 |
Orgenesis Provides Business Update for the Third Quarter of 2023
|
Nov 8 |
Orgenesis announces pricing of $1.1M registered direct offering
|
Nov 8 |
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
|
Nov 2 |
Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding
|